CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Drug
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...
Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval
China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...
Precigen’s RRP Therapy PRGN-2012 Gets FDA Review
US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...
InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum
Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...
Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...
Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow...
Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...
Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy
Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial
YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...
Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...
Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients
Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...
Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval
China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...
CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study
Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...